Shares of ImmunoGen, Inc. (NASDAQ:IMGN – Get Free Report) have received an average rating of “Hold” from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $25.77.
A number of equities analysts have recently commented on the company. Barclays restated an “equal weight” rating and issued a $31.00 price objective (up from $27.00) on shares of ImmunoGen in a report on Friday, December 1st. Guggenheim downgraded shares of ImmunoGen from a “buy” rating to a “neutral” rating and raised their target price for the company from $25.00 to $31.00 in a research note on Friday, December 1st. Deutsche Bank Aktiengesellschaft began coverage on shares of ImmunoGen in a research note on Thursday, November 9th. They issued a “buy” rating and a $25.00 target price on the stock. HC Wainwright lowered ImmunoGen from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $28.00 to $31.26 in a research report on Thursday, November 30th. Finally, William Blair lowered shares of ImmunoGen from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 30th.
Check Out Our Latest Analysis on ImmunoGen
Insider Buying and Selling
Institutional Investors Weigh In On ImmunoGen
Several large investors have recently made changes to their positions in IMGN. Vazirani Asset Management LLC acquired a new stake in ImmunoGen in the 4th quarter valued at approximately $25,000. Parallel Advisors LLC increased its stake in ImmunoGen by 3,028.6% during the 4th quarter. Parallel Advisors LLC now owns 876 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 848 shares during the period. Cary Street Partners Investment Advisory LLC acquired a new position in ImmunoGen during the 2nd quarter valued at about $28,000. BluePath Capital Management LLC acquired a new position in ImmunoGen during the 3rd quarter valued at about $35,000. Finally, McGlone Suttner Wealth Management Inc. acquired a new position in ImmunoGen during the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 90.50% of the company’s stock.
ImmunoGen Price Performance
Shares of IMGN opened at $31.23 on Tuesday. The firm has a market cap of $8.32 billion, a PE ratio of -100.74 and a beta of 1.18. The company’s fifty day moving average is $30.15 and its two-hundred day moving average is $22.21. ImmunoGen has a fifty-two week low of $3.61 and a fifty-two week high of $31.25. The company has a quick ratio of 5.65, a current ratio of 5.70 and a debt-to-equity ratio of 0.13.
ImmunoGen Company Profile
ImmunoGen, Inc, a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
Featured Stories
- Five stocks we like better than ImmunoGen
- What is a Secondary Public Offering? What Investors Need to Know
- MarketBeat Week in Review – 2/26 – 3/1
- How to Use the MarketBeat Dividend Calculator
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- The Most Important Warren Buffett Stock for Investors: His Own
- Snowflake Stock Plunges, Don’t be Fooled, Bargain Alert
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.